Regional cerebral blood flow changes in Parkinson's disease: correlation with disease duration;Cambios de la perfusión cerebral en la enfermedad de Parkinson: relación con la duración de los síntomas

Revista Espanola de Medicina Nuclear

Volumn 28, Issue 3, 2009, Pages 114-120

  Kapitan M ^a   Ferrando, R ^a   Dieguez E ^b   de Medina, O ^b   Aljanati, R ^b   Ventura, R ^b   Amorin, I ^b   Salinas, D ^b   Langhain, M ^a   Gioia, A ^a   Cardoso, A ^a   Lago, G ^a   Buzo R ^b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b Instituto de Neurología Hospital   (Uruguay)

Author keywords

Brain SPECT; Disease duration; Parkinson's disease; Regional cerebral blood flow

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; LEVODOPA;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN PERFUSION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MALE; MOTOR CONTROL; PARIETAL LOBE; PARKINSON DISEASE; PREMOTOR CORTEX; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBTHALAMIC NUCLEUS; THALAMUS;

ADULT; AGED; CEREBELLUM; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67649171710     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(09)71353-9     Document Type: Article

References (25)

1. Herrero M.T., Barcia C., and de Pablos V. Patogenia y etiología de la enfermedad de Parkinson. In: Micheli F. (Ed). Enfermedad de Parkinson y trastornos relacionados (2006), Médica Panamericana, Buenos Aires 119-153
2. Heriksen L., and Boas J. Regional cerebral blood flow in hemiparkinsonian patients: emission computerized tomography of inhaled 133 Xenon before and after levodopa. Acta Neurol Scand 71 (1985) 257-266
3. Martin W.R., Beckman J.H., Calne D.B., Adam M.J., Harrop R., Rogers J.G., et al. Cerebral glucose metabolism in Parkinsońs disease. Can J Neurol Sci 11 (1984) 169-173
4. Miletich R.S., Quarantelli M., and Chiro G. Regional cerebral blood flow imaging with 99mTc-bicisate SPECT in asymmetric Parkinson's disease: studies with and without chronic drug therapy. J Cereb Blood Flow Metab 14 (1994) S106-S114
5. Rougemont D., Baron J.C., Collard P., Bustany P., Comar D., and Agid Y. Local cerebral metabolic rate of glucose (ICMRglc) in treated and untreated patients with Parkinson's disease. J Cereb Blood Flow Metab 3 (1983) S504-S505
6. Pizzolato G., Dam M., Borsato N., Saitta B., Da Col C., Perlotto, et al. [99mTc]-HMPAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab 8 (1988) S101-S108
7. Kuhi D.E., Metter E.l., and Reige W.H. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the (18 F) fluorodeoxyglucose method. Ann Neurol 15 (1984) 419-424
8. Lenzi G.L., Jone T., Reid G.L., and Moss S. Regional impairment of cerebral oxydative metabolism in Parkinson's disease. J Neurol Nerosurg Psychiatry 22 (1979) 59-62
9. Perlmutter J.S., and Raichle M.E. Regional blood flow in hemiparkinsonism. Neurology 35 (1985) 1127-1134
10. Hoehn M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
11. Imon Y., Matsuda H., Ogawa M., Kogure D., and Sunohara N. SPECT image analysis using Statistical Parametric Mapping in patients with Parkinson's disease. J NucI Med 40 (1999) 1583-1589
12. Van Laere K., Santens P., Bosman T., De Reuck J., Mortelmans L., and Dierckx R. Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 45 (2004) 933-942
13. Firbank M.J., Molloy S., McKeith I.G., Burn D.J., and O'Brien J.T. Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson's disease over one year. J Neurol Neurosurg Psychiatry 76 (2005) 1448-1451
14. Santens P., De Corte T., Vingerhoets G., Van Laere K., Dierckx R., and De Reuck J. Regional cerebral blood flow and episodic memory in Parkinson's disease: a Single Photon Emission Tomography study. Eur Neurol 49 (2003) 238-242
15. Wallin A., Ekberg S., Lind K., Milos V., Granérus A.K., and Granerus G. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease-a rCBF scintigraphy study. Acta Neurol Scand 116 (2007) 347-354
16. Derejko M., SΠawek J., Wieczorek D., Brockhuis B., Dubaniewicz M., and Lass P. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun 27 (2006) 945-951
17. Hu M.T., Taylor-Robinson S.D., Chaudhuri K.R., Bell J.D., Labbé C., Cunningham V.J., et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined 31P-MRS and 18FDG-PET study. Brain 123 (2000) 340-352
18. Quinn N., Critchley P., and Marsden C.D. Young onset Parkinson's disease. Mov Disord 2 (1987) 73-91
19. Friston K.J., Frith C.D., Liddle P.F., Dolan R.J., Lammertsma A.A., and Frackowiak R.S. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 10 (1990) 458-466
20. Friston K.J., Homes A.P., Worsley K.J., Poline J.-P., Frith C.D., and Frackowiak R.S. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2 (1995) 189-210
21. Eckert T., Tang Ch., and Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6 (2007) 926-932
22. Tachibana H., Tomino Y., Kawabata K., Sugita M., and Fukuchi M. Twelve-month follow-up study of regional cerebral blood flow in Parkinson's disease. Dementia 6 (1995) 89-93
23. Winogrodzka A., Bergmans P., Booij J., van Royen E.A., Janssen A.G., and Wolters E.C. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 108 (2001) 1011-1019
24. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (2001) 2089-2094
25. Hardie R.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET. J Neurol Neurosurg Psychiatry 66 (1999) 256